DelveInsight’s, “Alcoholic Hepatitis Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Alcoholic Hepatitis pipeline landscape. It covers the Alcoholic Hepatitis pipeline drug profiles, including Alcoholic Hepatitis clinical trials and nonclinical stage products. It also covers the Alcoholic Hepatitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Alcoholic Hepatitis Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Alcoholic Hepatitis Pipeline landscape @ Alcoholic Hepatitis Pipeline Outlook Report
Alcoholic Hepatitis Overview
Alcoholic hepatitis is an inflammatory condition of the liver caused by heavy alcohol consumption over an extended period of time. Ongoing alcohol use and binge drinking can both aggravate this condition. Continued drinking can lead to additional health conditions, such as cirrhosis, excessive bleeding, or even liver failure.
Recent Developmental Activities in the Alcoholic Hepatitis Treatment Landscape
For further information, refer to the detailed Alcoholic Hepatitis Drugs Launch, Alcoholic Hepatitis Developmental Activities, and Alcoholic Hepatitis News, click here for Alcoholic Hepatitis Ongoing Clinical Trial Analysis
Alcoholic Hepatitis Emerging Drugs Profile
DUR-928 is an investigational product and has not been approved by the FDA for marketing in the U.S. for any indication. DURECT is currently conducting a Phase IIb study (AHFIRM) in subjects with severe alcohol-associated hepatitis (also called Alcoholic Hepatitis or AH) to evaluate safety and efficacy of DUR-928 treatment. DUR-928 has been shown to inhibit the activity of DNMTs (DNMT-1, 3a and 3b), inhibiting DNA methylation, and upregulating expression of genes involved in signaling pathways associated with cell death, stress response, and lipid biosynthesis, which may ultimately result in increased cell survival, reduced inflammation, and decreased lipotoxicity.
Canakinumab is a licensed monoclonal antibody inhibitor of IL-1 and may consequently reverse the adverse effects of the cytokine in patients with this disorder. Therefore, the main objective of the Phase II ISAIAH trial is to explore the potential benefits of the IL-1β antibody, Canakinumab (solution for injection), in the treatment of alcoholic hepatitis.
Alcoholic Hepatitis Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Alcoholic Hepatitis. The companies which have their Alcoholic Hepatitis drug candidates in the most advanced stage, i.e. phase III include, Durect.
Find out more about the Alcoholic Hepatitis Diagnosis and Treatment of patients @ Alcoholic Hepatitis Ongoing Clinical Trials Analysis
Scope of the Alcoholic Hepatitis Pipeline Report
Discover more about the list of FDA-approved drugs for Alcoholic Hepatitis @ Alcoholic Hepatitis Treatment Landscape
Table of Content
For further information on the Alcoholic Hepatitis Pipeline therapeutics, reach out @ Alcoholic Hepatitis Market Drivers and Barriers
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/